Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2018 - 2026)

Compass Therapeutics' Shares Outstanding (Weighted Average) history runs 9 years deep, the most recent figure standing at $186.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 34.84% year-over-year to $186.4 million; the TTM figure through Mar 2026 stood at $186.4 million (up 34.84% YoY), while the FY2025 annual figure was $157.7 million, up 14.78% from the prior year.
• Shares Outstanding (Weighted Average) came in at $186.4 million for Q1 2026 at Compass Therapeutics, up from $157.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $186.4 million in Q1 2026 to a low of $100.9 million in Q1 2022.
• A 5-year average of $132.5 million and a median of $136.6 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) surged 96.55% in 2022 and climbed 0.85% in 2025, its largest moves.
• Compass Therapeutics' Shares Outstanding (Weighted Average) stood at $105.2 million in 2022, then gained by 20.76% to $127.0 million in 2023, then increased by 8.15% to $137.4 million in 2024, then grew by 14.78% to $157.7 million in 2025, then increased by 18.2% to $186.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $186.4 million, $157.7 million, and $168.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison